期刊文献+

利培酮口服液与利培酮片剂治疗老年期精神分裂症疗效与安全性的对照研究 被引量:3

A comparatire study of risperidone oral solution and risperidone tablets in the treatment of elderly schizophrenia
下载PDF
导出
摘要 目的比较利培酮口服液与利培酮片剂治疗老年期精神分裂症的疗效和安全性。方法将68例老年期精神分裂症患者随机分为利培酮口服液组和利培酮片剂组。疗程8周,使用阳性与阴性症状量表评定临床疗效,使用副反应量表评定药物不良反应。结果两组在治疗后的第2周均起效,PANSS分数在两组治疗后的2、4、8周降低与治疗前比较其差异均有显著性(P<0.01);利培酮口服液组有效率85.7%,利培酮片剂组有效率87.9%;8周末利培酮口服液与片剂的不良反应主要为肌强直、震颤,约20%~25%,其次为失眠、便秘与食欲差等,约9%~11%,但上述症状发生均较轻,未经特殊处理。两组不良反应发生率比较其差异无显著性(P>0.01)。结论利培酮口服液与利培酮片剂治疗老年期精神分裂症有相同的疗效,安全性高、耐受性好。与利培酮片剂相比口服液给药途径方便,更适合老年患者使用。 Objective To compare the efficacy and safety of risperidone oral solution and risperidone tablets in the treatment of elderly schizophrenia. Methods A total of 68 aged patients with schizophrenia were randomly divided into risperidone oral solution group and risperidone tablets group respectively for 8 weeks of treatment. The efficacy was evaluated by Positive and Negative Symptom Scale (PANSS),and the side effects by Treatment Emergent Symptom Scale (TESS). Results Efficacy of two groups started in the 2nd weekend after treatment. Significant differences were found in the reduction of PANSS score between each stage (respectively in the 2nd,4th ,8th week after treatment)and baseline in both groups(P〈0.01). The effective rate in risperidone oral solution group was 85.7% ,and in risperidone tablets group was 87.9%. The efficacy and side effects of two groups at the end of 8th week were mainly myotonia and tremor(20%-25%), then insomnia, constipation and bad appetite(9%-11%) and there were no significant differences between two groups. Conclusion Risperidone oral solution has high safety , good tolerability and similar curative effects to risperidone tablets, and more convenient administration route which is more suitable for elderly patients .
机构地区 天津市安定医院
出处 《精神医学杂志》 2008年第2期92-94,共3页 Journal of Psychiatry
关键词 老年期精神分裂症 利培酮口服液 利培酮片剂 Elderly schizophrenia Risperidone oral solution Risperidone tablet
  • 相关文献

参考文献6

  • 1[1]Leonard White,Joseph I.Friedman.Christopher R.Bowie,et al.Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia:Retrospective comparison of first generation and second generation antipsychotics[J].Schizophrenia Research,2006,88:127-134
  • 2[2]Anton J.M.Loonen.Jacques C.M.Loos,Theodora H.Van Zonneveld.Outcomes and costs of treatment with risperidone in adult and elderly patients:the Delta patient using risperidone study[J].Progress in Neuro-Psyehopharmacology and Biological Psychiatry,2002,26:1313-1318
  • 3王泽鉴,杜兴水,王俊兰.利培酮治疗老年期精神分裂症对照研究[J].临床精神医学杂志,2005,15(5):289-290. 被引量:5
  • 4平其能.口腔崩解片的研究及开发[J].中国医药技术与市场,2004,4(4):13-15. 被引量:25
  • 5[6]Gutierrez R.Lee PI,Huang ML.et al.Risperidone:Effects of Formulations on oral Bioavailability[J].phovrmacotheraPy,1997,17:599-605
  • 6寻知元.药物干预与改善分裂症患者的依从性[J].国际精神病学杂志,2007,34(1):39-42. 被引量:11

二级参考文献19

  • 1Tuhe LE,salzman C.Schizophrenia in late life[J].Psychiat Clin North Am,2003,26:104-113.
  • 2Bloch Y, Mendlovic S, Strupimky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry, 2001; 62 (11): 855-859.
  • 3Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003; 33 (1) : 83-89.
  • 4Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an anfipsychotic: clinical studies. J Clin Psychiatry, 2003; 64 (Suppl 16) : 34-40.
  • 5Stein R, Preisman O, Alfici S, et al. A long-acting second generation anti-psychotic-experience in Israel. Harefuah. 2004; 143 (6): 408-409.
  • 6Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics, 2005; 23 (3): 299-314.
  • 7Treloar A, Beats B, Philpot M. A pill in the sandwich: Covert medication in food and drink. Journal of the Royal Society of Medicine, 2000; 93 : 408-411.
  • 8Srinivasan TN, Thara R. Management of medication noncompliance in schizophrenia by the families in India. Schizophrenia Bulletin, 2002; 28 (3): 531-535.
  • 9Eaddy M, Grogg A,Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a medical population. Clin Ther. 2005; 27 (2): 263-272.
  • 10Misdrahi D, Llorca PM, Lancon C, et al. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale. 2002; 28 (3): 266- 272.

共引文献38

同被引文献39

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部